FDA Panel Critical of Drisapersen Data in DuchenneFDA Panel Critical of Drisapersen Data in Duchenne

FDA reviewers and advisory committee panel members were critical of drisapersen data, suggesting they may not provide the evidence needed for approval for Duchenne muscular dystrophy. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news